Table 4. Results of the analyses of factors associated with 5-year recurrence-free survival after liver transplantation for hepatocellular cancer.
| Factors | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Recipient male gender | 1.21 (0.45–3.23) | 0.701 | ||
| Recipient age | 0.98 (0.94–1.02) | 0.380 | ||
| MELD | 0.95 (0.86–1.06) | 0.361 | ||
| HCV infection | 0.80 (0.36–1.78) | 0.583 | ||
| HBV infection | 1.80 (0.82–3.95) | 0.142 | ||
| Alcoholic liver disease | 1.08 (0.40–2.88) | 0.879 | ||
| Number of tumors | 1.27 (1.13–1.43) | <.001 | 1.18 (1.01–1.38) | 0.047 |
| Size of the largest tumor | 1.39 (1.19–1.62) | <.001 | 1.33 (1.13–1.56) | <.001 |
| Total tumor volume | 1.03 (1.01–1.04) | <.001 | ||
| Pre-transplant AFP | 1.43 (1.23–1.66) | <0.001 | 1.45 (1.20–1.75) | <.001 |
| Poor tumor differentiation | 3.53 (1.47–8.48) | 0.005 | 2.95 (1.05–8.25) | 0.039 |
| Microvascular invasion | 2.52 (1.15–5.52) | 0.021 | ||
| Neoadjuvant treatment | 1.82 (0.83–4.01) | 0.136 | ||
| Donor age (years) | 0.99 (0.96–1.02) | 0.573 | ||
Hazard ratios were given per: 1 year increase for recipient and donor age; 1 point increase for model for end-stage liver disease; 1 tumor more for number of tumors; 1 cm increase for the size of the largest tumor; 10 cm3 increase for total tumor volume; 1 loge increase for alpha-fetoprotein. HR – hazard ratio; 95% CI – 95% confidence interval; MELD – model for end-stage liver disease; HCV – hepatitis C virus; HBV – hepatitis B virus; AFP – alpha-fetoprotein.